Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400MM
Intellia Therapeutics, a biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, entered into a...






